# Comparing Telehealth and In-person Assessments in Glioma Patients Receiving Oral Chemotherapy

> **NCT06625047** · PHASE4 · COMPLETED · sponsor: **Mayo Clinic** · enrollment: 30 (actual)

## Conditions studied

- Astrocytoma, IDH-Mutant
- Glioblastoma
- Glioma
- Oligodendroglioma, IDH-Mutant and 1p/19q-Codeleted

## Interventions

- **BEHAVIORAL:** Assessment
- **OTHER:** Questionnaire Administration
- **OTHER:** Telemedicine Visit
- **DRUG:** Temozolomide

## Key facts

- **NCT ID:** NCT06625047
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-10-07
- **Primary completion:** 2025-11-12
- **Final completion:** 2025-11-12
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2026-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06625047

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06625047, "Comparing Telehealth and In-person Assessments in Glioma Patients Receiving Oral Chemotherapy". Retrieved via AI Analytics 2026-07-03 from https://api.ai-analytics.org/clinical/NCT06625047. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*